JP2019502371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502371A5 JP2019502371A5 JP2018526190A JP2018526190A JP2019502371A5 JP 2019502371 A5 JP2019502371 A5 JP 2019502371A5 JP 2018526190 A JP2018526190 A JP 2018526190A JP 2018526190 A JP2018526190 A JP 2018526190A JP 2019502371 A5 JP2019502371 A5 JP 2019502371A5
- Authority
- JP
- Japan
- Prior art keywords
- ortholog
- cmv
- active
- protein
- mir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701022 Cytomegalovirus Species 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 101150016730 UL79 gene Proteins 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 101150088910 UL82 gene Proteins 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 108700011259 MicroRNAs Proteins 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 108091008875 B cell receptors Proteins 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000021309 Germ cell tumor Diseases 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 241000282560 Macaca mulatta Species 0.000 claims description 3
- 108091028080 MiR-132 Proteins 0.000 claims description 3
- 108091033773 MiR-155 Proteins 0.000 claims description 3
- 108091062140 Mir-223 Proteins 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 108091064282 miR-125 stem-loop Proteins 0.000 claims description 3
- 108091037066 miR-125-1 stem-loop Proteins 0.000 claims description 3
- 108091062107 miR-125-2 stem-loop Proteins 0.000 claims description 3
- 108091079767 miR-125-3 stem-loop Proteins 0.000 claims description 3
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 3
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 3
- 108091032320 miR-146 stem-loop Proteins 0.000 claims description 3
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 3
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 3
- -1 miR-27a Proteins 0.000 claims description 3
- 108091050734 miR-652 stem-loop Proteins 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000012045 magnetic resonance elastography Methods 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 101150085955 US11 gene Proteins 0.000 description 10
- 230000030279 gene silencing Effects 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022135565A JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258393P | 2015-11-20 | 2015-11-20 | |
| US62/258,393 | 2015-11-20 | ||
| US201662365259P | 2016-07-21 | 2016-07-21 | |
| US62/365,259 | 2016-07-21 | ||
| PCT/US2016/062973 WO2017087921A1 (en) | 2015-11-20 | 2016-11-20 | Cmv vectors comprising microrna recognition elements |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022135565A Division JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502371A JP2019502371A (ja) | 2019-01-31 |
| JP2019502371A5 true JP2019502371A5 (cg-RX-API-DMAC7.html) | 2019-12-26 |
| JP7133468B2 JP7133468B2 (ja) | 2022-09-08 |
Family
ID=58719315
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526190A Active JP7133468B2 (ja) | 2015-11-20 | 2016-11-20 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
| JP2022135565A Pending JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022135565A Pending JP2022174123A (ja) | 2015-11-20 | 2022-08-29 | マイクロｒｎａ認識エレメントを含むｃｍｖベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10688164B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3377636A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7133468B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116926128A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016355468B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3005136A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA43285A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017087921A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| ES2696703T3 (es) | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
| CA3113595A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | CASSETTES OF ANTIGENS OF TUBERCULOSIS |
| WO2020247859A2 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| US20220307054A1 (en) | 2019-08-20 | 2022-09-29 | Oregon Health & Science University | Modulation of t cell responses by ul18 of human cytomegalovirus |
| WO2021168405A1 (en) | 2020-02-21 | 2021-08-26 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| IL310663A (en) | 2021-08-31 | 2024-04-01 | Vir Biotechnology Inc | Recombinant hcmv vectors and uses thereof |
| EP4396208A1 (en) | 2021-08-31 | 2024-07-10 | VIR Biotechnology, Inc. | Tuberculosis vaccines |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3853139T2 (de) | 1987-06-26 | 1995-06-14 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| JP2708960B2 (ja) * | 1990-08-16 | 1998-02-04 | アイシス・ファーマシューティカルス・インコーポレーテッド | サイトメガウイルス感染の作用を変調するオリゴヌクレオチド |
| SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
| WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| JPH09512177A (ja) | 1994-04-29 | 1997-12-09 | ファルマシア・アンド・アップジョン・カンパニー | ネコ免疫不全ウイルスワクチン |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| AU711121B2 (en) | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| JPH11503024A (ja) | 1995-04-04 | 1999-03-23 | セル・ジェネシス・インコーポレイテッド | 細胞表面のクラスｉ ｍｈｃタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植 |
| ES2237800T3 (es) | 1996-07-31 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | Identificacion de genes del citomegalovirus humano implicados en la retro-regulacion de la expresion de las cadenas pesadas de la clase i del cmh. |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
| US6884785B2 (en) * | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) * | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| IL160809A0 (en) | 2001-09-20 | 2004-08-31 | Glaxo Group Ltd | HIV-gag CODON-OPTIMISED DNA VACCINES |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| JP2005523942A (ja) | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) * | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| EP2497831B1 (en) | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| CN101990439A (zh) | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | 具有置于c末端的特异性结合结构域的结合肽 |
| RU2498991C2 (ru) | 2007-10-30 | 2013-11-20 | Дженентек, Инк. | Очистка антител с помощью катионообменной хроматографии |
| US8074351B2 (en) * | 2008-07-25 | 2011-12-13 | Panasonic Corporation | Part mounting device and part mounting method |
| CA2754826A1 (en) * | 2009-03-06 | 2010-09-10 | Mount Sinai School Of Medicine | Live attenuated influenza virus vaccines comprising microrna response elements |
| MX2012007489A (es) | 2009-12-23 | 2012-11-29 | 4Antibody Ag | Miembros enlazadores para citomegalovirus. |
| EP2529227B1 (en) | 2010-01-27 | 2015-10-07 | Oregon Health & Science University | Cytomegalovirus-based immunogenic preparations |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| JP2013527758A (ja) | 2010-05-05 | 2013-07-04 | ティリオン，クリスティアン | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
| SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| EP3623478A1 (en) * | 2012-10-25 | 2020-03-18 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| US8903341B2 (en) * | 2012-12-05 | 2014-12-02 | Qualcomm Incorporated | Successive interference cancellation (SIC) ordering algorithms for improved multiple-input multiple-output (MIMO) performance |
| ES2696703T3 (es) | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
| CA3113595A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| CA3028002A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2016
- 2016-11-20 CA CA3005136A patent/CA3005136A1/en active Pending
- 2016-11-20 US US15/356,627 patent/US10688164B2/en active Active
- 2016-11-20 CN CN202310470923.2A patent/CN116926128A/zh active Pending
- 2016-11-20 MA MA043285A patent/MA43285A/fr unknown
- 2016-11-20 AU AU2016355468A patent/AU2016355468B2/en not_active Ceased
- 2016-11-20 EP EP16867316.8A patent/EP3377636A4/en active Pending
- 2016-11-20 JP JP2018526190A patent/JP7133468B2/ja active Active
- 2016-11-20 CN CN201680075638.9A patent/CN108474003A/zh active Pending
- 2016-11-20 WO PCT/US2016/062973 patent/WO2017087921A1/en not_active Ceased
-
2020
- 2020-05-08 US US16/870,766 patent/US20200368333A1/en not_active Abandoned
-
2022
- 2022-08-29 JP JP2022135565A patent/JP2022174123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502371A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531745A5 (cg-RX-API-DMAC7.html) | ||
| Capone et al. | Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials | |
| Johansson et al. | Intradermal electroporation of naked replicon RNA elicits strong immune responses | |
| Kallen et al. | A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines | |
| JP2018510650A5 (cg-RX-API-DMAC7.html) | ||
| Donnelly et al. | DNA vaccines: progress and challenges | |
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| Zhou et al. | Cancer vaccines: current status and future directions | |
| JP2017522312A5 (cg-RX-API-DMAC7.html) | ||
| van de Wall et al. | Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens | |
| JP2017524348A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509163A5 (cg-RX-API-DMAC7.html) | ||
| CN110944675A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| JP2017513478A5 (cg-RX-API-DMAC7.html) | ||
| Lin et al. | Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity | |
| JP2019502371A (ja) | マイクロｒｎａ認識エレメントを含むｃｍｖベクター | |
| Goyvaerts et al. | The journey of in vivo virus engineered dendritic cells from bench to bedside: a bumpy road | |
| Tenbusch et al. | Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques | |
| JP2019508044A5 (cg-RX-API-DMAC7.html) | ||
| RU2021109510A (ru) | Вакцинация с использованием альфа 3 домена mica/b для лечения рака | |
| WO2017161360A4 (en) | Multimodal vector for dendritic cell infection | |
| Acres et al. | Clinical development of MVA-based therapeutic cancer vaccines | |
| Freitas-Silva et al. | Dendritic cell-based approaches in the fight against diseases | |
| Zhang et al. | Hepatitis B virus core antigen epitopes presented by HLA‐A2 single‐chain trimers induce functional epitope‐specific CD8+ T‐cell responses in HLA‐A2· 1/Kb transgenic mice |